Iovance Biotherapeutics, Inc. is a biopharmaceutical based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
History The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became Lion Bio Pharma, which was then rebranded to Iovance in 2017. In 2024, the US FDA gave accelerated approval to Lifileucel, marketed under the brand name Amtagvi, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma. TIL monotherapy and TIL combination therapies are being investigated by Iovance in multiple clinical studies in multiple advanced solid tumor cancers such as NSCLC and sarcoma.
See also Kite Pharma
References
External links Official website Business data for Iovance Biotherapeutics, Inc.: